Cargando…

Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis

Our meta-analysis aggregated existing results from relevant studies to comprehensively investigate the correlations between genetic polymorphisms in dihydropyrimidine dehydrogenase (DPYD) gene and 5-fluorouracil (5-FU) toxicities in patients with colorectal cancer (CRC). The MEDLINE (1966∼2013), the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qiang, Liu, Ying, Zhang, Hong-Mei, Huang, Yin-Peng, Wang, Tian-Yi, Li, Dong-Sheng, Sun, Hong-Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295351/ https://www.ncbi.nlm.nih.gov/pubmed/25614737 http://dx.doi.org/10.1155/2014/827989

Ejemplares similares

Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Research and Practice, Gastroenterology
Publicado: (2020)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
por: Hishinuma, Eiji, et al.
Publicado: (2022)

Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients
por: K, Ashok Varma, et al.
Publicado: (2019)

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
por: Wigle, Theodore J., et al.
Publicado: (2019)

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
por: Amstutz, Ursula, et al.
Publicado: (2008)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil
por: Winquist, Lauren E., et al.
Publicado: (2020)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients
por: Savva-Bordalo, Joana, et al.
Publicado: (2010)

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
por: De Luca, Ottavia, et al.
Publicado: (2022)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients
por: Amirfallah, Arsalan, et al.
Publicado: (2018)

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant
por: Majounie, Elisa, et al.
Publicado: (2020)

Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient
por: Bukhari, Nedal, et al.
Publicado: (2019)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
por: Negarandeh, Reza, et al.
Publicado: (2020)

Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report
por: Mukherji, Deborah, et al.
Publicado: (2019)

Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity
por: Ockeloen, Charlotte W, et al.
Publicado: (2021)

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis
por: Liu, Dan, et al.
Publicado: (2017)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
por: Bukhari, Nedal, et al.
Publicado: (2021)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil
por: Kuang, Yan-Shen, et al.
Publicado: (2018)

Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity
por: Hamzic, Seid, et al.
Publicado: (2021)

Impact of DPYD, DPYS, and UPB1 gene variations on severe drug‐related toxicity in patients with cancer
por: Yokoi, Katsuyuki, et al.
Publicado: (2020)

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS
por: Rosmarin, Dan, et al.
Publicado: (2015)

The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
por: Saif, Muhammad W, et al.
Publicado: (2016)

The Effect of Compound Sophora on Fluorouracil and Oxaliplatin Resistance in Colorectal Cancer Cells
por: Yin, WeiHua, et al.
Publicado: (2019)

Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil
por: Schmulenson, Eduard, et al.
Publicado: (2022)

Frequency of the DPYD * 2A allele in the Czech population
por: Koudová, Monika, et al.
Publicado: (2014)

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
por: Villalvazo, Priscila, et al.
Publicado: (2021)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
por: Desilets, Antoine, et al.
Publicado: (2022)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dq4nha730416op947gsn7r2857